Striking results from hemophilia A trials carried out at research institutes in London have been described as potentially “transformational” by the lead investigator.
Professor John Pasi said: "It's ground-breaking because the option to think about normalizing levels in patients with severe hemophilia is absolutely mind-blowing."
The 18-month data from the Phase I/II trial, published in the New England Journal of Medicine, show sustained factor VIII levels, within the normal range, for most patients with severe hemophilia A.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze